Literature DB >> 14991874

The effectiveness of complete decongestive physiotherapy for the treatment of lymphedema following groin dissection for melanoma.

Christian S Hinrichs1, John F Gibbs, Deborah Driscoll, James L Kepner, Neal W Wilkinson, Stephen B Edge, Kathleen A Fassl, Robin Muir, William G Kraybill.   

Abstract

OBJECTIVE: Groin dissection is performed for the treatment of melanoma and other malignancies. Lymphedema rates as high as 47% have been reported. In 1996, we began using complete decongestive physiotherapy (CDP) in selected patients with lymphedema following groin dissection. Here, we review our results in a small cohort of patients.
METHODS: A retrospective review of the medical records of 14 patients, treated with CDP for lymphedema secondary to groin dissection for melanoma was conducted. All patients were treated with CDP at Roswell Park Cancer Institute (RPCI), between 1996 and 2002. Of the 14 patients, 12 underwent groin dissection at RPCI. Response to therapy was measured by limb volume determinations. Patient gender, age, body mass index (BMI), type of operation, type of adjuvant therapy, time to treatment, patient compliance, lymphedema stage, and initial edema were analyzed for association with response to treatment. Incidence was estimated by a review of the operative logs.
RESULTS: Fourteen patients were treated with CDP for lymphedema secondary to groin dissection for melanoma, with a median decrease in lymphedema of 60% (range: 35-145%; P = 0.0003). Increased BMI was associated with a decreased response to treatment (P = 0.02). Response to CDP was not effected by time to treatment, patient compliance, lymphedema stage, and initial edema. During this time, 39 groin dissections were done at RPCI. The incidence of lymphedema treated with CDP at RPCI was 31% (12/39; standard error 7.4%).
CONCLUSIONS: With a decrease in lymphedema of 60%, CDP may provide relief for patients with lymphedema following groin dissection. Elevated BMI was associated with a decreased response to CDP. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 14991874     DOI: 10.1002/jso.20020

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Weight lifting in patients with lower-extremity lymphedema secondary to cancer: a pilot and feasibility study.

Authors:  Elana Katz; Nicole L Dugan; Joy C Cohn; Christina Chu; Rebecca G Smith; Kathryn H Schmitz
Journal:  Arch Phys Med Rehabil       Date:  2010-07       Impact factor: 3.966

2.  Effectiveness of the treatment-phase of two-phase complex decongestive physiotherapy for the treatment of extremity lymphedema.

Authors:  Ritsu Yamamoto; Terumi Yamamoto
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

3.  Impact of aggressive decongestion on the maintenance phase in combined physical therapy for lower extremity lymphedema.

Authors:  Kotaro Suehiro; Noriyasu Morikage; Osamu Yamashita; Yohikazu Okazaki; Kimikazu Hamano Md
Journal:  Ann Vasc Dis       Date:  2011-11-15

4.  The Lymph-Sparing Quotient: A Retrospective Risk Analysis on Extremity Radiation for Soft Tissue Sarcoma Treatment.

Authors:  Iqbal Sarif; Khaled Elsayad; Daniel Rolf; Christopher Kittel; Georg Gosheger; Eva Wardelmann; Uwe Haverkamp; Hans Theodor Eich
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

5.  Mechanisms of lymphatic regeneration after tissue transfer.

Authors:  Alan Yan; Tomer Avraham; Jamie C Zampell; Seth Z Aschen; Babak J Mehrara
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

6.  Evidence Mapping of the Treatments for Breast Cancer-related Lymphedema.

Authors:  Ali M Al-Sakkaf; Jaume Masia; Ariadna Auladell-Rispau; Aliaa I Shamardal; Luis Vasconcello-Castillo; Ivan Sola; Xavier Bonfill
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-01-18

Review 7.  A comprehensive overview on the surgical management of secondary lymphedema of the upper and lower extremities related to prior oncologic therapies.

Authors:  Ramon Garza; Roman Skoracki; Karen Hock; Stephen P Povoski
Journal:  BMC Cancer       Date:  2017-07-05       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.